Medtronic Rapid Exchange Stent Systems Require License For U.S. Marketing
This article was originally published in The Gray Sheet
Executive Summary
Medtronic would need to pursue a license agreement with Boston Scientific in order to keep its rapid exchange coronary stent systems on the U.S. market, following an adverse arbitration panel ruling July 18.
You may also be interested in...
Boston Scientific Predicts IVT Revenues Will Balloon Following Acquisition
Boston Scientific remains committed to ongoing merger negotiations with Medinol despite its $345 mil. cash acquisition of Interventional Technologies, which gives it access to IVT's LP coronary stent line.
Boston Scientific Seeks To Defend Rapid-Exchange Patents In U.S., Abroad
Boston Scientific is seeking to defend the intellectual property gained through its $2.1 bil. Schneider buy in 1998 by filing suit against Medtronic claiming infringement of a rapid-exchange catheter patent.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.